Quantcast

Latest glioblastoma multiforme Stories

2014-03-06 08:29:14

NEW YORK, March 6, 2014 /PRNewswire/ -- SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The note is focuses on DelMar Pharmaceuticals...

2014-03-05 23:03:44

Project Impact aims to fundamentally change the way new pediatric cancer therapies are developed and tested, through public policy and a funded research program. Boston, MA (PRWEB) March 05, 2014 National Brain Tumor Society, the largest nonprofit dedicated to the brain tumor community in the United States, today announced the launch of Project Impact: Driving Discovery to a Cure for Pediatric Brain Tumors, an integrated research and drug development program that seeks to confront the...

2014-03-04 08:31:55

VANCOUVER, British Columbia and MENLO PARK, Calif., March 4, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") a pharmaceutical company developing its VAL-083 chemotherapy as a potential new therapy for glioblastoma multiforme, today announced that Jeffrey A. Bacha, President and CEO of DelMar Pharmaceuticals, Inc., will present at the upcoming 26(th) Annual ROTH Capital Conference. Mr. Bacha will make a corporate presentation to...

2014-02-26 23:02:51

Jumpstarting Brain Tumor Drug Development Coalition hosts seminal workshop with brain tumor patient advocates, leading neuro-oncologists, biopharmaceutical industry representatives, FDA, and NCI to advance strategies for establishing better pathways for therapy evaluation. Bethesda, MD (PRWEB) February 26, 2014 Leaders from key cross-sections of the neuro-oncology community came together at a recent Brain Tumor Clinical Trial Endpoints Workshop to confront a critical challenge in...

2014-02-26 08:28:38

Interim clinical data to be presented at American Association of Cancer Research (AACR) Annual Meeting on April 9, 2014 VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 26, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") provided an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 5 and advanced to Cohort 6. DelMar...

2014-02-25 08:30:35

LOS ANGELES, Feb. 25, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during...

2014-02-18 08:32:26

The NovoTAL System Enables Certified Physicians to Plan and Individualize NovoTTF(TM) Therapy for Recurrent Glioblastoma Patients NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Novocure announced today that Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center has licensed the NovoTAL (Transducer Array Layout) System. The NovoTAL System allows certified physicians to use a recurrent GBM patient's MRI data to optimize the distribution and intensity of NovoTTF Therapy....

2014-02-14 16:25:28

Featured Talk Emphasizes Importance of Antigen-Specific Dendritic Cell Cancer Vaccines to Generate Powerful T-Cell Response LOS ANGELES, Feb. 14, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the Company's Founder and Chief Scientific Officer, John S. Yu, MD, delivered a presentation highlighting the therapeutic importance of utilizing antigen-specific dendritic cell (DC) cancer vaccines for inducing a potent T-cell...

2014-02-06 08:28:58

BETHESDA, Md., Feb. 6, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the BIO CEO and Investor Conference 2014, which is being held in New York on February 10-11, 2014. NW Bio's presentation will take place on Monday, February 10, at 11:30 a.m. EST in the Basildon Room at the Waldorf-Astoria in New York...

2014-02-05 23:25:30

Moving the Needle in Brain Tumor Survivorship through Genomic Sequencing Seattle, WA (PRWEB) February 05, 2014 On January 22nd, 2014 the Chris Elliott Fund (CEF) and Foundation Medicine co-hosted a dinner in Seattle to share some of the latest developments in genomic profiling and the implications for brain tumor patients everywhere. The evening brought together a number of people from the Seattle Metro area: including patients, advocates, scientists, and physicians from Swedish Medical...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'